Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

FibroGen's Novel Anemia Treatment Meets Phase III Endpoints in China

publication date: Jan 30, 2017
FibroGen, a US-China novel drug company, reported positive results from two China Phase III trials of roxadustat, a treatment for anemia. Roxadustat is a first-in-class, oral small molecule treatment for anemia in chronic kidney disease. In 2013, FibroGen formed a 50/50 joint venture with AstraZeneca to develop roxadustat in China. AstraZeneca paid $28.2 million upfront and agreed to a total of $328.5 million in milestones. FibroGen will manufacture the drug in China through its China subsidiary, while AstraZeneca will be in charge of commercialization. More details....

Stock Symbols: (NSDQ: FGEN) (NYSE: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital